Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Senseonics Holdings Stock Sank Today

By Keith Speights - Jul 18, 2019 at 3:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dilution is on the way, causing at least temporary pain for shareholders.

What happened

Shares of Senseonics Holdings ( SENS -1.59% ) were sinking 14.3% as of 3:12 p.m. EDT on Thursday. The big drop came after the medical technology company announced the pricing of a public offering of its stock.

So what

The math for public stock offerings is pretty simple. As more shares become available for purchase, the value of existing shares goes down -- typically by a similar percentage as the increase in outstanding shares. This shareholder dilution creates pain for investors, at least temporarily.

Line chart going down with numbers on digital board in background

Image source: Getty Images.

Senseonics is creating more than 27.2 million additional shares for its stock offering. That represents around 12.8% of the company's current outstanding shares, which is pretty close to how much the stock fell today.

The price of a stock offering is also important. Senseonics priced its latest stock offering at $1.10 per share. Unsurprisingly, its share price promptly dropped to near that level.  

There was some good news with Senseonics' announcement, though. The company will generate around $25 million in gross proceeds, most of which will go toward funding operations. Senseonics also announced the pricing of an offering of convertible senior notes due in 2025. This transaction will raise an additional $77 million in net proceeds, $37 million of which will be used to repurchase convertible senior notes that are due in 2023.

Now what

Senseonics' primary challenge is to boost sales of its Eversense implantable continuous glucose monitoring (CGM) system. The company announced earlier this week that it expects second-quarter revenue between $4.4 million and $4.7 million. That's not enough to even come close to covering expenses.

But Senseonics thinks that momentum will pick up for Eversense. CEO Tim Goodnow expressed confidence that there will be increased adoption of the CGM system in the second half of 2019. If he's right, today's dilution-caused decline could be only a temporary pullback.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Senseonics Holdings, Inc. Stock Quote
Senseonics Holdings, Inc.
SENS
$3.09 (-1.59%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.